| Balance Sheets | 2026-06-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 6,962,492 | |||
| Accounts receivable, net of allownace of 9,023,768 as of june 30, 2026 and december 31, 2025, respectively | 6,621,357 | |||
| Inventory | 4,711,775 | |||
| Prepaid expenses and other assets | 2,485,430 | |||
| Total current assets | 20,781,054 | |||
| Total property and equipment | 5,795,848 | |||
| Less accumulated depreciation | 1,376,285 | |||
| Property and equipment, net | 4,419,563 | |||
| Construction-in-process | 505,307 | |||
| Right-of-use asset, net | 220,551 | |||
| Intangible assets, net | 21,359,186 | |||
| Goodwill | 1,532,635 | |||
| Total assets | 48,818,296 | |||
| Accounts payable and accrued expenses | 9,457,957 | |||
| License fees payable | 434,775 | |||
| Income tax payable | 0 | |||
| Accrued interest | 11,333 | |||
| Operating lease liabilities | 222,471 | |||
| Notes payable | 1,000,000 | |||
| Contingent consideration payable | 10,000,000 | |||
| Other current liabilities | 75,808 | |||
| Total current liabilities | 21,202,344 | |||
| Operating lease liabilities, less current portion | 1,355 | |||
| Total long-term liabilities | 1,355 | |||
| Total liabilities | 21,203,699 | |||
| Preferred stock value-Series AOne Convertible Preferred Shares | 0 | |||
| Preferred stock value-Series BOne Convertible Preferred Shares | 0 | |||
| Common stock, 0.001 par value authorized 975,000,000 shares issued and outstanding 17,839,467 and 16,825,716 shares as of june 30, 2026 and december 31, 2025, respectively | 17,841 | |||
| Additional paid-in capital | 66,605,483 | |||
| Treasury stock, 18,000 shares at cost | 43,346 | |||
| Accumulated deficit | -38,965,381 | |||
| Total stockholders' equity | 27,614,597 | |||
| Total liabilities and stockholders' equity | 48,818,296 | |||
BioStem Technologies, Inc. (BSEM)
BioStem Technologies, Inc. (BSEM)